Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Puja Sapra

Showing results (11-20 of 56) with videos related to

Pageof 6
Sort By:
Pharmaceutical Research|January 15, 2015
Evolving Strategies for Target Selection for Antibody-Drug ConjugatesMarc Damelin, Wenyan Zhong, Jeremy Myers, et al.
Biochemical Pharmacology|December 22, 2015
Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?Hans-Peter Gerber, Puja Sapra, Frank Loganzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2004
Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragmentsPuja Sapra, Elaine H Moase, Jie Ma, et al.
Expert Opinion on Investigational Drugs|May 24, 2011
Investigational antibody drug conjugates for solid tumorsPuja Sapra, Andrea T Hooper, Christopher J O'Donnell, et al.
Journal of Liposome Research|February 27, 2003
Adventures in targetingTheresa M Allen, Puja Sapra, Elaine Moase, et al.
Nature Cancer|February 22, 2023
Advances in antibody-based therapy in oncologySacha Zinn, Rodrigo Vazquez-Lombardi, Carsten Zimmermann, et al.
Nucleosides, Nucleotides & Nucleic Acids|April 15, 2010
Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotidePuja Sapra, Maoliang Wang, Raj Bandaru, et al.
Cell|April 17, 2026
Targeting genomic instability in cancerTimothy A Yap, H Charles Manning, Puja Sapra, et al.
Molecular Pharmaceutics|November 26, 2014
Phenotype of TPBG Gene Replacement in the Mouse and Impact on the Pharmacokinetics of an Antibody-Drug ConjugateGeorge Hu, Mauricio Leal, Qingcong Lin, et al.
Haematologica|October 2, 2009
Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphomaPuja Sapra, Patricia Kraft, Mary Mehlig, et al.
Pageof 6

Showing results (11-20 of 56) with videos related to

Sort By:
Pageof 6
Pharmaceutical Research|January 15, 2015
Evolving Strategies for Target Selection for Antibody-Drug ConjugatesMarc Damelin, Wenyan Zhong, Jeremy Myers, et al.
Biochemical Pharmacology|December 22, 2015
Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?Hans-Peter Gerber, Puja Sapra, Frank Loganzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2004
Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragmentsPuja Sapra, Elaine H Moase, Jie Ma, et al.
Expert Opinion on Investigational Drugs|May 24, 2011
Investigational antibody drug conjugates for solid tumorsPuja Sapra, Andrea T Hooper, Christopher J O'Donnell, et al.
Journal of Liposome Research|February 27, 2003
Adventures in targetingTheresa M Allen, Puja Sapra, Elaine Moase, et al.
Nature Cancer|February 22, 2023
Advances in antibody-based therapy in oncologySacha Zinn, Rodrigo Vazquez-Lombardi, Carsten Zimmermann, et al.
Nucleosides, Nucleotides & Nucleic Acids|April 15, 2010
Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotidePuja Sapra, Maoliang Wang, Raj Bandaru, et al.
Cell|April 17, 2026
Targeting genomic instability in cancerTimothy A Yap, H Charles Manning, Puja Sapra, et al.
Molecular Pharmaceutics|November 26, 2014
Phenotype of TPBG Gene Replacement in the Mouse and Impact on the Pharmacokinetics of an Antibody-Drug ConjugateGeorge Hu, Mauricio Leal, Qingcong Lin, et al.
Haematologica|October 2, 2009
Marked therapeutic efficacy of a novel polyethylene glycol-SN38 conjugate, EZN-2208, in xenograft models of B-cell non-Hodgkin's lymphomaPuja Sapra, Patricia Kraft, Mary Mehlig, et al.
Pageof 6